Current Cardiology Reports

, 13:537

Apo A-I Modulating Therapies

Lipid Abnormalities and Cardiovascular Prevention (Michael H. Davidson, Section Editor)

DOI: 10.1007/s11886-011-0223-0

Cite this article as:
Nicholls, S.J. Curr Cardiol Rep (2011) 13: 537. doi:10.1007/s11886-011-0223-0


The substantial residual risk of cardiovascular events despite the implementation of effective lowering of low-density lipoprotein cholesterol highlights the need to develop additional cardioprotective therapies. Evidence from population and animal studies suggests that high-density lipoproteins (HDLs), the protective lipid particles, may represent a target for therapeutic modification. As a result intensive efforts are in progress to develop new agents that promote HDL activity. Among these different approaches, a range of strategies that target apolipoprotein A-I, the major protein carried on HDL, are being evaluated.


Apolipoprotein A-IHigh-density lipoproteinsRisk factorsAtherosclerosisLipidsCoronary artery disease

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Department of Cardiovascular MedicineHeart & Vascular Institute, Cleveland ClinicClevelandUSA